Truth matters. Community matters. Your support makes both possible. LAist is one of the few places where news remains independent and free from political and corporate influence. Stand up for truth ...
Caribou Biosciences, Inc. experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. CB-010 showed limited efficacy in ...
Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Quiver AI Summary Greenwich LifeSciences, Inc.
Determining the specificity of HLA antibodies is arguably one of the most important contributions by the HLA laboratory today. For patients that have low-to-moderate levels of antibody, using a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback